From Lab to Life: Brain Cancer Breakthrough

Cancer is a disease that is especially infuriating.   

Consider children. The World Health Organization notes that around 400,000 total cancer cases are diagnosed annually across children and adolescents). Many prove fatal.

There is something especially tragic and angering when those who have barely begun their lives find them in danger of ending.

New hope comes from research from the University of California – San Francisco. According to Science Daily, “Scientists have engineered immune cells that switch on inside the brain, completely wiping out deadly childhood brain tumors in mice and remaining active to fight the cancer if it returns.” **

** Senthilnath Lakshmanachetty, Milos S. Simic, Payal B. Watchmaker, Robert Zhu, Takahide Nejo, Maggie Colton Cove, Jeffrey Haegelin, Haoyu Long, Aishi Zhao, Alejandra Bergquist, Wei Yu, Brianna Wong, Marco Gallus, Ricardo Almeida, Joanna P. Phillips, Wendell A. Lim, Hideho Okada. Brain-sensing synNotch–CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science Translational Medicine, 2026; 18 (873) DOI: 10.1126/scitranslmed.aed9994

“In experiments involving mice, scientists engineered cells that successfully eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that spreads into surrounding healthy tissue. Nearly all children diagnosed with the disease die within a year, and existing treatments have had little success in stopping its progression.” Thousands of children die from it globally. And there was no hope. Until now.

Here is the background.

It starts with CAR-T cells. “CAR-T therapy works by modifying the body’s T cells, a type of immune cell, so they carry special receptors called CARs. These receptors recognize proteins on cancer cells and trigger an immune attack. Although CAR-T treatments have shown success against certain cancers, brain tumors have remained particularly difficult to overcome.”

Why? “It’s been a struggle to make CAR-T cells that overcome DMG without causing unacceptable side effects,” said Hideho Okada, MD, PhD, a professor of Neurological Surgery at UCSF and co-corresponding author of the study.”

In 2021, Scientists  reported encouraging laboratory findings with an earlier therapy called E-SYNC, designed to treat glioblastoma, another aggressive form of brain cancer.  E-SYNC uses a molecular sensing system known as synNotch to identify EGFRvIII, a mutated protein found on some glioblastoma cells.

When this protein is detected, synNotch directs the immune cell to produce a CAR that recognizes two additional tumor-associated proteins, EphA2 and IL13Rα2. This two-step process proved more effective than conventional CAR-T strategies that rely on a single activation step.

However, the approach had an important limitation. Only about 20% of patients have tumors containing EGFRvIII. Even when the protein is initially present, tumors can lose it as treatment eliminates the cancer cells carrying it. This allows remaining cancer cells to escape detection.

To overcome that problem, the researchers searched for a more dependable signal that could activate the therapy in a wider range of patients.

And they used remarkable creativity.

“The scientists identified brevican, a protein naturally distributed throughout the brain, as a promising alternative.  They redesigned the synNotch system so that it would trigger CAR production only when it encountered brevican. Once activated, these “B-SYNC” CAR-T cells could search for cancer cells carrying EphA2 or IL13Rα2, even if those cells lacked EGFRvIII.”

This is like police searching for an escaped criminal, and focusing on his known haunts – home, family, friends, pub.  Fire off those anti-cancer CAR cells only when they know they are in the brain – because the trigger protein only exists in the brain.

Kudos to the brilliant scientists. Let’s hope many kids’ lives will be saved as a result.